Health Care • Biotechnology: Pharmaceutical Preparations
$3.49 ▼ -0.28
(-7.43%)
MKT CAP: $7.9M • VOL: 37.9K
52W L $2 52W H $22
ROARABLE / RQD
E • 34/100
PIOTROSKI
4 / 9
LEXX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-08-31 | FY 2024
FILED 2024-08-31 | FY 2023
FILED 2023-08-31 |
|---|---|---|---|
| Revenue (Total Sales) | $705.9K | $464.3K | $226.2K |
| YoY Revenue Growth % | +52.0% | +105.2% | — |
| Gross Profit | $703.2K | $459.5K | — |
| Gross Margin % | 98.0% | 98.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$11.9M | -$5.8M | -$6.5M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$11.9M | -$5.8M | -$6.7M |
| EBITDA (Normalized) | -$11.9M | -$5.7M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$10.5M | -$5.0M | -$5.9M |
| Capital Expenditures (CapEx) | $24.6K | $43.0K | — |
| Free Cash Flow (FCF) | -$10.5M | -$5.0M | -$5.9M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $4.3M | — | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $4.9M | $9.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR LEXX.